300146 汤臣倍健
交易中 05-18 14:35:12
资讯
新帖
简况
汤臣倍健：公司目前未投资DeepSeek
证券之星 · 05-15 17:00
汤臣倍健：公司目前未投资DeepSeek
东吴证券：给予汤臣倍健买入评级
证券之星 · 05-12
东吴证券：给予汤臣倍健买入评级
汤臣倍健：公司始终重视抗衰老领域的科研探索与技术积累
证券之星 · 05-11
汤臣倍健：公司始终重视抗衰老领域的科研探索与技术积累
汤臣倍健：公司已递交轻络素相关的新功能申报及产品注册申请
证券之星 · 05-07
汤臣倍健：公司已递交轻络素相关的新功能申报及产品注册申请
汤臣倍健：公司以消费者健康需求为核心，始终重视抗衰老领域的科研探索与技术积累
证券之星 · 05-07
汤臣倍健：公司以消费者健康需求为核心，始终重视抗衰老领域的科研探索与技术积累
汤臣倍健：公司沉心提质，积极适应市场环境及渠道变化持续优化业务策略
证券之星 · 04-28
汤臣倍健：公司沉心提质，积极适应市场环境及渠道变化持续优化业务策略
汤臣倍健(300146)3月31日股东户数6.49万户，较上期增加0.49%
证券之星 · 04-25
汤臣倍健(300146)3月31日股东户数6.49万户，较上期增加0.49%
汤臣倍健(300146.SZ)发布一季度业绩，归母净利润4.02亿元，下降11.62%
智通财经 · 04-24
汤臣倍健(300146.SZ)发布一季度业绩，归母净利润4.02亿元，下降11.62%
股市必读：汤臣倍健（300146）4月22日董秘有最新回复
证券之星 · 04-23
股市必读：汤臣倍健（300146）4月22日董秘有最新回复
汤臣倍健：上述新功能申报及产品注册申请的补充材料已提交
证券之星 · 04-22
汤臣倍健：上述新功能申报及产品注册申请的补充材料已提交
汤臣倍健：调节肠道菌群、增强免疫力
证券之星 · 04-22
汤臣倍健：调节肠道菌群、增强免疫力
汤臣倍健：公司希望通过做强主业为投资者创造长期价值
证券之星 · 04-15
汤臣倍健：公司希望通过做强主业为投资者创造长期价值
汤臣倍健：拟每10股分红4.50元（含税）
证券日报 · 04-13
汤臣倍健：拟每10股分红4.50元（含税）
汤臣倍健：公司旗下“左旋肉碱茶多酚荷叶片”保健食品具有减肥的保健功能
证券之星 · 04-13
汤臣倍健：公司旗下“左旋肉碱茶多酚荷叶片”保健食品具有减肥的保健功能
汤臣倍健：公司已递交轻络素相关的新功能申报及产品注册申请
证券之星 · 04-13
汤臣倍健：公司已递交轻络素相关的新功能申报及产品注册申请
汤臣倍健：加速科研成果向具有核心竞争力的产品转化
证券之星 · 04-07
汤臣倍健：加速科研成果向具有核心竞争力的产品转化
股市必读：汤臣倍健（300146）4月3日董秘有最新回复
证券之星 · 04-07
股市必读：汤臣倍健（300146）4月3日董秘有最新回复
汤臣倍健：公司是此项国家标准的起草单位之一
证券之星 · 04-04
汤臣倍健：公司是此项国家标准的起草单位之一
汤臣倍健：2026年计划实现营业收入同比双位数增长
证券之星 · 03-27
汤臣倍健：2026年计划实现营业收入同比双位数增长
汤臣倍健：国家尚未将“降低发生心源性猝死风险”列为可声称的保健功能
证券之星 · 03-27
汤臣倍健：国家尚未将“降低发生心源性猝死风险”列为可声称的保健功能
公司概况
公司名称：
汤臣倍健股份有限公司
所属行业：
食品制造业
上市日期：
2010-12-15
主营业务：
汤臣倍健股份有限公司的主营业务是膳食营养补充剂的生产销售。公司的主要产品是片剂、粉剂、胶囊、其他。截至报告期末，公司已获得145项原料及配方等发明专利。
发行价格：
110.00
{"stockData":{"symbol":"300146","market":"SZ","secType":"STK","nameCN":"汤臣倍健","latestPrice":10.03,"timestamp":1779086112000,"preClose":10.17,"halted":0,"volume":12067873,"delay":0,"changeRate":-0.0138,"floatShares":1121000000,"shares":1692000000,"eps":0.4312,"marketStatus":"交易中","change":-0.14,"latestTime":"05-18 14:35:12","open":10.2,"high":10.2,"low":10.02,"amount":122000000,"amplitude":0.0177,"askPrice":10.04,"askSize":1077,"bidPrice":10.03,"bidSize":1965,"shortable":0,"etf":0,"ttmEps":0.4312,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1779087600000},"marketStatusCode":2,"adr":0,"adjPreClose":10.17,"symbolType":"stock","openAndCloseTimeList":[[1779067800000,1779075000000],[1779080400000,1779087600000]],"highLimit":11.19,"lowLimit":9.15,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":1691677031,"isCdr":false,"pbRate":1.49,"roa":"--","peRate":23.260668,"roe":"3.55%","epsLYR":0.47,"committee":0.741291,"marketValue":16968000000,"turnoverRate":0.0108,"status":1,"floatMarketCap":11240000000},"requestUrl":"/m/hq/s/300146/wiki","defaultTab":"wiki","newsList":[{"id":"2635702783","title":"汤臣倍健：公司目前未投资DeepSeek","url":"https://stock-news.laohu8.com/highlight/detail?id=2635702783","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635702783?lang=zh_cn&edition=full","pubTime":"2026-05-15 17:00","pubTimestamp":1778835640,"startTime":"0","endTime":"0","summary":"证券之星消息，汤臣倍健(300146)05月15日在投资者关系平台上答复投资者关心的问题。投资者提问：公司是否直接或间接投的投资了DeepSeek公司？公司后续是否考虑增加月之暗面公司的投资？汤臣倍健回复：投资者您好！公司目前未投资DeepSeek，具体情况请以公司公告为准。感谢关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051500029899.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300146"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634263649","title":"东吴证券：给予汤臣倍健买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2634263649","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634263649?lang=zh_cn&edition=full","pubTime":"2026-05-12 11:57","pubTimestamp":1778558251,"startTime":"0","endTime":"0","summary":"东吴证券股份有限公司苏铖,邓洁近期对汤臣倍健进行研究并发布了研究报告《磨砺以须，倍道而进》，给予汤臣倍健买入评级。对应PE23、22、20x，考虑到公司C端基础佳，新渠道、新市场探索积极，我们认为当下估值仍具性价比，首次覆盖，给予“买入”评级。最新盈利预测明细如下：该股最近90天内共有9家机构给出评级，买入评级3家，增持评级5家，中性评级1家；过去90天内机构目标均价为12.35。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051200018274.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["601555","300146"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634240071","title":"汤臣倍健：公司始终重视抗衰老领域的科研探索与技术积累","url":"https://stock-news.laohu8.com/highlight/detail?id=2634240071","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634240071?lang=zh_cn&edition=full","pubTime":"2026-05-11 18:36","pubTimestamp":1778495773,"startTime":"0","endTime":"0","summary":"证券之星消息，汤臣倍健05月11日在投资者关系平台上答复投资者关心的问题。请问公司的在研抗衰项目和上述项目比有哪些优势？公司始终重视抗衰老领域的科研探索与技术积累，持续跟踪国内外前沿科学动态，通过相关前瞻性基础研究及成果转化等，持续打造产品力和科技竞争力优势。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051100028838.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0226","BK0146","BK0107","BK0028","300146","BK0042","BK0114"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633111078","title":"汤臣倍健：公司已递交轻络素相关的新功能申报及产品注册申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2633111078","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633111078?lang=zh_cn&edition=full","pubTime":"2026-05-07 18:30","pubTimestamp":1778149820,"startTime":"0","endTime":"0","summary":"证券之星消息，汤臣倍健(300146)05月07日在投资者关系平台上答复投资者关心的问题。投资者提问：你好，轻络素的新功能技术审评进入行政批复了没有？对于这个研发11年的大单品，公司是否有做好了上市前期的所有准备？请如实回答，谢谢！汤臣倍健回复：投资者您好！公司已递交轻络素相关的新功能申报及产品注册申请，目前尚在审批中。感谢关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050700031701.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0146","300146","BK0226","BK0107","BK0114","BK0042"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633110873","title":"汤臣倍健：公司以消费者健康需求为核心，始终重视抗衰老领域的科研探索与技术积累","url":"https://stock-news.laohu8.com/highlight/detail?id=2633110873","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633110873?lang=zh_cn&edition=full","pubTime":"2026-05-07 18:21","pubTimestamp":1778149264,"startTime":"0","endTime":"0","summary":"证券之星消息，汤臣倍健(300146)05月07日在投资者关系平台上答复投资者关心的问题。投资者提问：公司能否在抗衰老产品上培育利润增长点？汤臣倍健回复：投资者您好！公司以消费者健康需求为核心，始终重视抗衰老领域的科研探索与技术积累，持续跟踪国内外前沿科学动态。国家市场监督管理总局目前尚未将“抗衰老”单独列为可声称的保健功能，公司将在符合法规要求的框架下，为消费者提供高品质的健康选择。感谢关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050700031464.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0114","BK0107","BK0028","BK0042","BK0226","300146","BK0146"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630370526","title":"汤臣倍健：公司沉心提质，积极适应市场环境及渠道变化持续优化业务策略","url":"https://stock-news.laohu8.com/highlight/detail?id=2630370526","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630370526?lang=zh_cn&edition=full","pubTime":"2026-04-28 18:18","pubTimestamp":1777371509,"startTime":"0","endTime":"0","summary":"证券之星消息，汤臣倍健04月28日在投资者关系平台上答复投资者关心的问题。请勿用标准化话术搪塞汤臣倍健回复：投资者您好！公司业绩表现受外部消费环境、行业竞争格局、渠道格局变化及公司的主动调整等多重因素影响，公司沉心提质，积极适应市场环境及渠道变化持续优化业务策略，围绕消费者需求持续优化产品组合，不断提升精细化管理能力，确保公司长期健康发展，回报广大投资者。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042800054306.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0107","BK0028","BK0226","BK0042","300146","BK0114","BK0146"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630870633","title":"汤臣倍健(300146)3月31日股东户数6.49万户，较上期增加0.49%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630870633","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630870633?lang=zh_cn&edition=full","pubTime":"2026-04-25 17:11","pubTimestamp":1777108313,"startTime":"0","endTime":"0","summary":"证券之星消息，近日汤臣倍健披露，截至2026年3月31日公司股东户数为6.49万户，较2月28日增加319.0户，增幅为0.49%。在食品加工行业个股中，汤臣倍健股东户数高于行业平均水平，截至3月31日，食品加工行业平均股东户数为3.26万户。从股价来看，2026年2月28日至2026年3月31日，汤臣倍健区间跌幅为8.96%，在此期间股东户数增加319.0户，增幅为0.49%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042500032625.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0146","BK0226","BK0107","BK0042","300146","BK0114"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629825196","title":"汤臣倍健(300146.SZ)发布一季度业绩，归母净利润4.02亿元，下降11.62%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629825196","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629825196?lang=zh_cn&edition=full","pubTime":"2026-04-24 23:51","pubTimestamp":1777045896,"startTime":"0","endTime":"0","summary":"智通财经APP讯，汤臣倍健(300146.SZ)发布2026年第一季度报告，该公司营业收入为18.69亿元，同比增长4.30%。归属于上市公司股东的净利润为4.02亿元，同比减少11.62%。归属于上市公司股东的扣除非经常性损益的净利润为3.75亿元，同比减少8.19%。基本每股收益为0.24元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1433859.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300146"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629202425","title":"股市必读：汤臣倍健（300146）4月22日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2629202425","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629202425?lang=zh_cn&edition=full","pubTime":"2026-04-23 02:49","pubTimestamp":1776883783,"startTime":"0","endTime":"0","summary":"截至2026年4月22日收盘，汤臣倍健报收于10.66元，下跌0.56%，换手率0.86%，成交量9.59万手，成交额1.02亿元。董秘最新回复投资者： 尊敬的董秘你好：近期，益生菌减肥的效果被社会关注。公司旗下相关益生菌产品的保健功能以“调节肠道菌群、增强免疫力”为主。公司对自有益生菌菌株进行了多项体外、动物及人体临床试验研究，以发掘其调节糖脂代谢、体重控制、肠道屏障修复、降尿酸等多方面的功效。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042300005057.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0107","BK0042","BK0114","BK0226","300146","BK0028","BK0146"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629019522","title":"汤臣倍健：上述新功能申报及产品注册申请的补充材料已提交","url":"https://stock-news.laohu8.com/highlight/detail?id=2629019522","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629019522?lang=zh_cn&edition=full","pubTime":"2026-04-22 17:18","pubTimestamp":1776849485,"startTime":"0","endTime":"0","summary":"证券之星消息，汤臣倍健04月22日在投资者关系平台上答复投资者关心的问题。上述新功能申报及产品注册申请的补充材料已提交，目前尚在审批中。公司业绩表现受外部消费环境、行业竞争格局、渠道格局变化及公司的主动调整等多重因素影响，公司将持续优化业务策略，发挥科研创新优势，不断打造与提升科技力、产品力、品牌力、渠道力、服务力等核心竞争力，以保持公司的市场领先地位。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042200039601.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0226","BK0146","300146","BK0107","BK0114","BK0028","BK0042"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629193570","title":"汤臣倍健：调节肠道菌群、增强免疫力","url":"https://stock-news.laohu8.com/highlight/detail?id=2629193570","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629193570?lang=zh_cn&edition=full","pubTime":"2026-04-22 17:12","pubTimestamp":1776849126,"startTime":"0","endTime":"0","summary":"证券之星消息，汤臣倍健04月22日在投资者关系平台上答复投资者关心的问题。公司旗下相关益生菌产品的保健功能以“调节肠道菌群、增强免疫力”为主。公司对自有益生菌菌株进行了多项体外、动物及人体临床试验研究，以发掘其调节糖脂代谢、体重控制、肠道屏障修复、降尿酸等多方面的功效。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042200039202.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300146","BK0107","BK0042","BK0226","BK0028","BK0114","BK0146"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627283353","title":"汤臣倍健：公司希望通过做强主业为投资者创造长期价值","url":"https://stock-news.laohu8.com/highlight/detail?id=2627283353","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627283353?lang=zh_cn&edition=full","pubTime":"2026-04-15 18:00","pubTimestamp":1776247250,"startTime":"0","endTime":"0","summary":"证券之星消息，汤臣倍健04月15日在投资者关系平台上答复投资者关心的问题。2021年公司市值已经600多亿了。市值受内外部多种因素影响，内因如公司策略有效性和经营表现，外因如行业板块估值和情绪等，公司希望通过做强主业为投资者创造长期价值。2025年薪酬变动幅度亦受2024年基数低影响。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041500034760.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0226","BK0146","300146","BK0107","BK0114","BK0028","BK0042"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627456781","title":"汤臣倍健：拟每10股分红4.50元（含税）","url":"https://stock-news.laohu8.com/highlight/detail?id=2627456781","media":"证券日报 ","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627456781?lang=zh_cn&edition=full","pubTime":"2026-04-13 21:20","pubTimestamp":1776086400,"startTime":"0","endTime":"0","summary":"证券日报网讯 4月13日，汤臣倍健发布公告称，公司2025年年度权益分派方案为：以公司现有总股本剔除已回购股份后的1，675，158，844股为基数，向全体股东每10股派发人民币4.50元现金（含税）。本次权益分派股权登记日为：2026年4月20日，除权除息日为：2026年4月21日。（文章来源：证券日报）\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-04-13/doc-inhukkny4708453.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-04-13/doc-inhukkny4708453.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0107","VIG","BK0042","BK0114","BK0226","BK4588","300146","BK0028","BK4585","BK0146"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627437717","title":"汤臣倍健：公司旗下“左旋肉碱茶多酚荷叶片”保健食品具有减肥的保健功能","url":"https://stock-news.laohu8.com/highlight/detail?id=2627437717","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627437717?lang=zh_cn&edition=full","pubTime":"2026-04-13 19:36","pubTimestamp":1776080164,"startTime":"0","endTime":"0","summary":"证券之星消息，汤臣倍健(300146)04月13日在投资者关系平台上答复投资者关心的问题。投资者提问：尊敬的董秘你好：贵公司保健产品齐全，想问一下，有没有减肥功效的产品？如有，请详细的介绍一下。谢谢！汤臣倍健回复：投资者您好！公司旗下“左旋肉碱茶多酚荷叶片”保健食品具有减肥的保健功能，产品详情可致电公司营养咨询热线4000916916。感谢关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041300028424.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","300146","BK0114","BK0146","BK0107","BK0226","BK0042"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627437400","title":"汤臣倍健：公司已递交轻络素相关的新功能申报及产品注册申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2627437400","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627437400?lang=zh_cn&edition=full","pubTime":"2026-04-13 19:33","pubTimestamp":1776079984,"startTime":"0","endTime":"0","summary":"证券之星消息，汤臣倍健(300146)04月13日在投资者关系平台上答复投资者关心的问题。投资者提问：请问公司的轻络素项目进展顺利吗？公司在项目审批过程中采取过哪些积极措施？公司身为行业龙头！一个产品上市要卡8年！因为公司是民营企业所以就被打压是吗？希望公司尽快落实对投资者的承诺！汤臣倍健回复：投资者您好！公司已递交轻络素相关的新功能申报及产品注册申请，目前尚在审批中。感谢关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041300028310.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0226","BK0146","BK0114","BK0042","300146","BK0107"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625939154","title":"汤臣倍健：加速科研成果向具有核心竞争力的产品转化","url":"https://stock-news.laohu8.com/highlight/detail?id=2625939154","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625939154?lang=zh_cn&edition=full","pubTime":"2026-04-07 17:48","pubTimestamp":1775555298,"startTime":"0","endTime":"0","summary":"证券之星消息，汤臣倍健04月07日在投资者关系平台上答复投资者关心的问题。投资者提问：公司2025年新品收入占比接近20%，并推出了首款自主研发的OTC产品等 。公司将围绕消费者健康需求，加速科研成果向具有核心竞争力的产品转化，深入开展重功能、新功能产品的临床研究，以市场需求与科学循证双轮驱动，实现产品力与品牌力升级。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040700024644.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300146","BK0226","BK0107","BK0114","BK0146","BK0042","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625604790","title":"股市必读：汤臣倍健（300146）4月3日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2625604790","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625604790?lang=zh_cn&edition=full","pubTime":"2026-04-07 05:10","pubTimestamp":1775509826,"startTime":"0","endTime":"0","summary":"截至2026年4月3日收盘，汤臣倍健报收于10.76元，下跌1.65%，换手率0.99%，成交量11.15万手，成交额1.2亿元。董秘最新回复投资者： 近期媒体报道网红销冠保健品“优思益”多平台下架!作为A股主板上市公司，汤臣倍健一直强调“诚信比聪明更重要”的质量理念 。这是否会凸显像汤臣倍健这样拥有透明工厂 、严格品控体系和大量境内专利及保健食品批文的企业的长期优势？","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040700002876.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0146","BK0226","BK0028","BK0114","300146","BK0107","BK0042"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624696106","title":"汤臣倍健：公司是此项国家标准的起草单位之一","url":"https://stock-news.laohu8.com/highlight/detail?id=2624696106","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624696106?lang=zh_cn&edition=full","pubTime":"2026-04-04 12:57","pubTimestamp":1775278626,"startTime":"0","endTime":"0","summary":"证券之星消息，汤臣倍健(300146)04月04日在投资者关系平台上答复投资者关心的问题。投资者提问：《保健食品原料益生菌》国标公开征求意见，汤臣倍健有参与吗？汤臣倍健回复：投资者您好！公司是此项国家标准的起草单位之一，通过将多年积累的科研数据、生产质控经验与行业洞察融入标准建设工作，推动益生菌原料的质量规范与科学应用。感谢关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040400005939.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300146","BK0226","BK0107","BK0028","BK0042","BK0114","BK0146"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622847076","title":"汤臣倍健：2026年计划实现营业收入同比双位数增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2622847076","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622847076?lang=zh_cn&edition=full","pubTime":"2026-03-27 18:12","pubTimestamp":1774606337,"startTime":"0","endTime":"0","summary":"证券之星消息，汤臣倍健(300146)03月27日在投资者关系平台上答复投资者关心的问题。投资者提问：你好，请问公司2026年一季度有哪些措施，可以让公司业绩增长达成双位数？汤臣倍健回复：投资者您好！2026年，公司计划实现营业收入同比双位数增长，将在多个渠道、多个重点品类进行突破。具体业务策略可查阅2025年年度报告经营计划相关内容。该目标的实现存在挑战和不确定性，不构成业绩承诺。感谢关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032700039902.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300146"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622784702","title":"汤臣倍健：国家尚未将“降低发生心源性猝死风险”列为可声称的保健功能","url":"https://stock-news.laohu8.com/highlight/detail?id=2622784702","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622784702?lang=zh_cn&edition=full","pubTime":"2026-03-27 18:09","pubTimestamp":1774606149,"startTime":"0","endTime":"0","summary":"证券之星消息，汤臣倍健(300146)03月27日在投资者关系平台上答复投资者关心的问题。投资者提问：请问公司有哪些产品能降低发生心源性猝死风险？汤臣倍健回复：投资者您好！国家市场监督管理总局目前尚未将“降低发生心源性猝死风险”单独列为可声称的保健功能。公司始终严格遵守国家相关法律法规，所有产品的功能声称均以国家批准的保健功能为准。感谢关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032700039823.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0042","BK0114","BK0107","BK0226","300146","BK0146","BK0028"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1779086116000,"stockEarnings":[{"period":"1week","weight":-0.0369},{"period":"1month","weight":-0.0532},{"period":"3month","weight":-0.1245},{"period":"6month","weight":-0.1671},{"period":"1year","weight":-0.0788},{"period":"ytd","weight":-0.1179}],"compareEarnings":[{"period":"1week","weight":-0.0107},{"period":"1month","weight":0.0269},{"period":"3month","weight":0.0131},{"period":"6month","weight":0.0363},{"period":"1year","weight":0.2232},{"period":"ytd","weight":0.042}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"汤臣倍健股份有限公司","boardCode":"AI0014","boardName":"食品制造业","stockholders":"64893人(较上一季度增加0.49%)","perCapita":"17269股","listingDate":"2010-12-15","address":"广东省珠海市金湾区三灶科技工业园星汉路19号","registeredCapital":"169167万元","survey":" 汤臣倍健股份有限公司的主营业务是膳食营养补充剂的生产销售。公司的主要产品是片剂、粉剂、胶囊、其他。截至报告期末，公司已获得145项原料及配方等发明专利。","listedPrice":110},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"汤臣倍健(300146)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供汤臣倍健(300146)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"汤臣倍健,300146,汤臣倍健股票,汤臣倍健股票老虎,汤臣倍健股票老虎国际,汤臣倍健行情,汤臣倍健股票行情,汤臣倍健股价,汤臣倍健股市,汤臣倍健股票价格,汤臣倍健股票交易,汤臣倍健股票购买,汤臣倍健股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"汤臣倍健(300146)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供汤臣倍健(300146)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}